<div id="readability-page-1"><p>Pharming Group (OTCMKTS:PHGUF - Get Free Report) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, Zacks reports. Pharming Group had a return on equity of 4.68% and a net margin of 3.30%.The firm had revenue of $72.45 million for the quarter, compared to analyst estimates of $92.06 million.</p><div><p><span></span><span>Get <strong>Pharming Group</strong> alerts:</span></p></div><h2>Pharming Group Stock Performance</h2><p>Shares of Pharming Group stock remained flat at $1.25 during mid-day trading on Friday. 5,071 shares of the company's stock traded hands, compared to its average volume of 390. Pharming Group has a one year low of $0.96 and a one year high of $2.17. The company has a market cap of $836.96 million, a PE ratio of 62.39 and a beta of 0.55. The stock has a fifty day moving average of $1.60 and a 200-day moving average of $1.65. The company has a quick ratio of 2.03, a current ratio of 2.59 and a debt-to-equity ratio of 0.39. </p><h2>Pharming Group Company Profile</h2> (Get Free Report)<p>Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.  </p><p>Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Pharming Group</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVBIR1VG?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVBIR1VG"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Pharming Group Right Now?</h2><p>Before you consider Pharming Group, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.</p><p>While Pharming Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

PHAR

SBIO

IBBQ

<p>Pharming Group (OTCMKTS:PHGUF) reported its quarterly earnings, showing a loss of ($0.01) EPS and revenue of $72.45 million, below analyst expectations of $92.06 million. The company has a return on equity of 4.68% and a net margin of 3.30%. Pharming's stock remained flat at $1.25, with a market cap of $836.96 million. The firm specializes in protein replacement therapies for rare diseases, with its main product RUCONEST approved in multiple regions.</p>

Pharming Group (OTCMKTS:PHGUF) Releases Quarterly Earnings Results